Comparable stake leader
HIGHBRIDGE CAPITAL MANAGEMENT LLC
SEC ownership of BioLineRx Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001498403.
Disclosed value leader
HIGHBRIDGE CAPITAL MANAGEMENT LLC
Comparable rows
17/17
Latest evidence
31 Mar 2026
- Public ticker
- BLRX on Nasdaq
- Parsed ownership sources
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- HIGHBRIDGE CAPITAL MANAGEMENT LLC
- Latest 13D/G holder
- HIGHBRIDGE CAPITAL MANAGEMENT LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001498403
- Issuer location
- Modi In
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BioLineRx Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
HIGHBRIDGE CAPITAL MANAGE...
Disclosed value leader
HIGHBRIDGE CAPITAL MANAGE...
Comparable rows
17/17
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 7.2%
13D/G row: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Showing 1-8 of 17 holder rows.
Quick read
HIGHBRIDGE CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 7.2%.
17 of 17 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens HIGHBRIDGE CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
HIGHBRIDGE CAPITAL MANAGEMENT LLC
7.2%
INTRACOASTAL CAPITAL, LLC
5%
Philip A. Serlin
0.21%
Aharon Schwartz
0.15%
Mali Zeevi
0.05%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 17 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13D/G
|
7.2%
|
$818,056,338
172,950,600 shares
|
$0 | 30 Jun 2025 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
$11,245,973
102,236,115 shares
|
$0 | 06 Jan 2025 |
| Philip A. Serlin |
3/4/5
Chief Executive Officer
|
0.21%
|
$14,225,349
5,131,800 shares
|
— | 18 Mar 2026 |
| Aharon Schwartz |
3/4/5
Director
|
0.15%
|
$10,270,260
3,705,000 shares
|
— | 18 Mar 2026 |
| Mali Zeevi |
3/4/5
Chief Financial Officer
|
0.05%
|
$3,775,680
1,311,000 shares
|
— | 18 Mar 2026 |
| XTX Topco Ltd |
13F
Company
|
0%
|
$25,274
10,941 shares
|
— | 31 Mar 2026 |
| RHUMBLINE ADVISERS |
13F
Company
|
0%
|
$5,432
2,353 shares
|
— | 31 Mar 2026 |
| BNP PARIBAS FINANCIAL MARKETS |
13F
Company
|
0%
|
$4,140
1,800 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to BioLineRx Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Philip A. Serlin
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Philip A. Serlin | Chief Executive Officer | $14,225,349 | Mixed | 18 Mar 2026 | ||
| Aharon Schwartz | Director | $10,270,260 | Mixed | 18 Mar 2026 | ||
| Mali Zeevi | Chief Financial Officer | $3,775,680 | Mixed | 18 Mar 2026 | ||
| Rami Dar | Director | Mixed | 18 Mar 2026 | |||
| Raphael Hofstein | Director | Mixed | 18 Mar 2026 | |||
| Sandra Panem | Director | Mixed | 18 Mar 2026 | |||
| Anne Bormann Kennedy | Director | Mixed | 18 Mar 2026 | |||
| Shaoyu Yan | Director | Mixed | 18 Mar 2026 | |||
| Gal Avraham Cohen | Director | Mixed | 18 Mar 2026 | |||
| Avraham Molcho | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for BioLineRx Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Aharon Schwartz | BLRX | Ordinary Shares, 0.1 NIS per share | 0 | 3,705,000 | 18 Mar 2026 | Direct | ||||
| Philip A. Serlin | BLRX | Ordinary Shares, 0.1 NIS per share | 0 | 5,131,800 | 18 Mar 2026 | Direct | ||||
| Mali Zeevi | BLRX | Ordinary Shares, 0.1 NIS per share | 0 | 1,311,000 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.